$354 Million is the total value of Casdin Capital, LLC's 26 reported holdings in Q3 2017. The portfolio turnover from Q2 2017 to Q3 2017 was 25.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| LOXO | LOXO ONCOLOGY INC | $33,163,000 | +14.9% | 360,000 | 0.0% | 9.36% | -12.3% | |
| MYOK | Buy | MYOKARDIA INC | $23,996,000 | +363.7% | 560,000 | +41.8% | 6.78% | +254.0% |
| ALNY | Buy | ALNYLAM PHARMACEUTICALS INC | $23,498,000 | +180.6% | 200,000 | +90.5% | 6.64% | +114.2% |
| SGMO | SANGAMO THERAPEUTICS INC | $21,000,000 | +70.5% | 1,400,000 | 0.0% | 5.93% | +30.1% | |
| BPMC | Buy | BLUEPRINT MEDICINES CORP | $20,762,000 | +49.0% | 298,000 | +8.4% | 5.86% | +13.7% |
| BLUE | Buy | BLUEBIRD BIO INC | $19,916,000 | +191.7% | 145,000 | +123.1% | 5.62% | +122.6% |
| FMI | FOUNDATION MEDICINE INC | $19,296,000 | +1.1% | 480,000 | 0.0% | 5.45% | -22.8% | |
| KITE | Buy | KITE PHARMA INC | $19,060,000 | +104.3% | 106,000 | +17.8% | 5.38% | +56.0% |
| ONCE | Buy | SPARK THERAPEUTICS INC | $18,677,000 | +83.9% | 209,474 | +23.2% | 5.27% | +40.4% |
| AGIO | AGIOS PHARMACEUTICALS INC | $17,021,000 | +29.7% | 255,000 | 0.0% | 4.81% | -1.0% | |
| VYGR | Buy | VOYAGER THERAPEUTICS INC | $16,781,000 | +153.1% | 815,000 | +10.1% | 4.74% | +93.2% |
| SAGE | Sell | SAGE THERAPEUTICS INC | $14,952,000 | -26.4% | 240,000 | -5.9% | 4.22% | -43.8% |
| GNMK | Buy | GENMARK DIAGNOSTICS INC | $14,445,000 | +78.2% | 1,500,000 | +119.0% | 4.08% | +36.1% |
| EVH | Buy | EVOLENT HEALTH INCcl a | $14,151,000 | +7.4% | 795,000 | +52.9% | 4.00% | -18.0% |
| GBT | Buy | GLOBAL BLOOD THERAPEUTICS IN | $11,799,000 | +100.7% | 380,000 | +76.7% | 3.33% | +53.2% |
| BOLD | AUDENTES THERAPEUTICS INC | $11,204,000 | +46.4% | 400,000 | 0.0% | 3.16% | +11.8% | |
| CLVS | Sell | CLOVIS ONCOLOGY INC | $10,506,000 | -13.7% | 127,500 | -1.9% | 2.97% | -34.1% |
| CDXS | Buy | CODEXIS INC | $9,809,000 | +51.2% | 1,475,000 | +23.9% | 2.77% | +15.5% |
| ILMN | Buy | ILLUMINA INC | $8,765,000 | +60.4% | 44,000 | +39.7% | 2.48% | +22.4% |
| JNCE | Buy | JOUNCE THERAPEUTICS INC | $6,229,000 | +177.5% | 399,825 | +149.9% | 1.76% | +111.9% |
| TSRO | Sell | TESARO INC | $4,970,000 | -26.0% | 38,500 | -19.8% | 1.40% | -43.5% |
| SYRS | Buy | SYROS PHARMACEUTICALS INC | $3,771,000 | +28.7% | 256,215 | +40.7% | 1.06% | -1.8% |
| CTMX | CYTOMX THERAPEUTICS INC | $3,225,000 | +17.2% | 177,500 | 0.0% | 0.91% | -10.5% | |
| EDIT | EDITAS MEDICINE INC | $3,201,000 | +43.1% | 133,333 | 0.0% | 0.90% | +9.3% | |
| FATE | FATE THERAPEUTICS INC | $2,178,000 | +22.2% | 550,000 | 0.0% | 0.62% | -6.7% | |
| OVID | Sell | OVID THERAPEUTICS INC | $1,778,000 | -23.6% | 207,500 | -6.4% | 0.50% | -41.6% |
| CRIS | Exit | CURIS INC | $0 | – | -85,000 | -100.0% | -0.06% | – |
| PACB | Exit | PACIFIC BIOSCIENCES CALIF IN | $0 | – | -300,000 | -100.0% | -0.40% | – |
| AMRS | Exit | AMYRIS INC | $0 | – | -500,000 | -100.0% | -0.59% | – |
| MDRX | Exit | ALLSCRIPTS HEALTHCARE SOLUTNcall | $0 | – | -150,000 | -100.0% | -0.71% | – |
| MYGN | Exit | MYRIAD GENETICS INCcall | $0 | – | -100,000 | -100.0% | -0.96% | – |
| GILD | Exit | GILEAD SCIENCES INCcall | $0 | – | -60,000 | -100.0% | -1.57% | – |
| GILD | Exit | GILEAD SCIENCES INC | $0 | – | -75,000 | -100.0% | -1.96% | – |
| EPZM | Exit | EPIZYME INC | $0 | – | -520,000 | -100.0% | -2.90% | – |
| XBI | Exit | SPDR SERIES TRUSTput | $0 | – | -150,000 | -100.0% | -4.28% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BLUEPRINT MEDICINES CORP | 32 | Q3 2023 | 9.6% |
| ALNYLAM PHARMACEUTICALS INC | 32 | Q3 2023 | 9.9% |
| AGIOS PHARMACEUTICALS INC | 27 | Q2 2022 | 12.1% |
| GLOBAL BLOOD THERAPEUTICS IN | 27 | Q2 2022 | 7.1% |
| FATE THERAPEUTICS INC | 26 | Q3 2023 | 8.3% |
| BIOLIFE SOLUTIONS INC | 22 | Q3 2023 | 14.9% |
| CODEXIS INC | 22 | Q3 2023 | 8.1% |
| SAREPTA THERAPEUTICS INC | 21 | Q3 2023 | 13.6% |
| BLUEBIRD BIO INC | 21 | Q4 2020 | 7.8% |
| ILLUMINA INC | 21 | Q3 2023 | 6.0% |
View Casdin Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Absci Corp | May 08, 2023 | 4,448,260 | 4.8% |
| CODEXIS, INC.Sold out | February 14, 2023 | 0 | 0.0% |
| DermTech, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Invitae Corp | February 14, 2023 | 9,038,388 | 3.7% |
| Magenta Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Tango Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Verve Therapeutics, Inc. | February 14, 2023 | 2,290,571 | 3.7% |
| Tenaya Therapeutics, Inc. | December 07, 2022 | 6,427,200 | 9.9% |
| Fulcrum Therapeutics, Inc. | February 11, 2021 | 1,241,176 | 4.5% |
| Gritstone Oncology, Inc.Sold out | February 11, 2021 | 0 | 0.0% |
View Casdin Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-18 |
| SC 13D/A | 2024-04-08 |
| 4 | 2024-03-28 |
| 3 | 2024-03-25 |
| 4 | 2024-03-25 |
| 4 | 2024-03-20 |
| SC 13D/A | 2024-03-20 |
| 4 | 2024-03-06 |
| 4 | 2024-03-06 |
| 13F-HR | 2024-02-14 |
View Casdin Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.